The Research Foundation for The State University of New York (USA)
Inventeur(s)
Zheng, Jian-Ping
Abrégé
A metal-seawater flow battery includes an anode disposed in a non-aqueous electrolyte and a cathode spaced apart from the anode. A metal-ion conductive membrane separates the anode from the cathode. The anode includes active metal. The cathode is configured to receive a flow of seawater therethrough. The cathode may be porous. For example, the cathode may include porous carbon (for example, carbon foam, carbon nanotubes, activated carbon, carbon black, or other forms of porous carbon, or combinations of different forms of porous carbon).
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Ackerman, Gary
Behlendorf, Brandon
Clifford, Douglas
Wetzel, Kristian
Peterson, Hayley
Latourette, Jenna
Abrégé
A system and method for conducting enhanced Red Teaming simulations across a network that provides a distributed, predefined or randomly generated dataset for Red Team testing to one or more participants across the network, such as a security breach or other adversarial scenario. The scenario is either predetermined or can experimentally vary the parameters of the scenario. A user interface is provided to show the distributed scenario dataset to one or more participants such that structured data gathering can be done from participant input with empirical results data being generated. The scenario dataset for Red Team testing can be iteratively simulated with predetermined variations in the predefined data, and the number of participants can accordingly be scaled across the network as needed.
H04L 41/22 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p. ex. des réseaux de commutation de paquets comprenant des interfaces utilisateur graphiques spécialement adaptées [GUI]
H04L 41/50 - Gestion des services réseau, p. ex. en assurant une bonne réalisation du service conformément aux accords
3.
OFF-GRID TURBINE-DRIVEN CENTRIFUGAL REVERSE OSMOSIS SYSTEM, AND APPLICATIONS THEREOF
The Research Foundation for The State University of New York (USA)
Cleveland State University Research Corporation (USA)
Inventeur(s)
Daskirian, Cosan
Usta, Mustafa
Abrégé
Integrated tidal desalination system that harnesses tidal power to produce drinkable water through a mechanically linked or direct drive integrated tidal turbine (ITT) and centrifugal reverse osmosis (CRO) system. The ITT-CRO system eliminates conversion losses in the power take-off unit by eliminating the need for electrical energy conversion. The ITT-CRO system is modelled, and the model used for control, and predictive maintenance.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Wan, Yong
Zhu, Yueming
Bahar, Ivet
Banerjee, Anupam
Lee, Jiyoung
Abrégé
Disclosed herein are pharmaceutical agents that inhibit or suppress OTUD4 and CD73 binding interactions; thus, useful in the context of managing diseases and conditions associated with OTUD4 and CD73 binding interactions, such as cancer treatments. In certain embodiments, this disclosure relates to method of treating cancer comprising administering an effective amount of a pharmaceutical agent that suppress OTUD4 and CD73 binding interactions. In certain embodiments, the therapeutic agent is a small molecule, antibody, or other specific binding agent.
THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (USA)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Zhang, Wei
Hu, Yiming
Yu, Miao
Sengupta, Bratin
Abrégé
A microporous crystalline lattice composition formed by a plurality of chemical subunits bound by a series of cross-linked covalent tetraphenoxyb orate linkages and weak ion-dipole interactions forming an ionic covalent organic framework (ICOF) having a plurality of tunable iso-surface channels.
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
6.
TRUNCATED TISSUE PLASMINOGEN ACTIVATOR PROTEINS AND USE THEREOF
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Danias, Ioannis
Abrégé
e.ge.g., AAV vectors) encoding the tPA variants. Also provided are pharmaceutical compositions comprising the tPA variants and vectors, and therapeutic uses of the pharmaceutical compositions to treat intraocular pressure (IOP)-associated conditions, such as glaucoma.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Parsons, Jack Gordon
Bond, Silas
Huggins, Penelope Jane
Kosman, Daniel Jacob
Bailey, Danielle Kristine
Nihlawi, Rhudwan
Abrégé
Provided herein are methods and uses of compounds for direct scavenging of and/or direct reduction of the concentration of one or more reactive oxygen species (ROS), and for therapy of associated diseases and disorders. Also provided herein are methods and uses of the compounds for preventing loss of, maintaining, or restoring mitochondrial function, and for therapy of associated diseases and disorders. Also provided herein are methods and uses of the compounds for treating or preventing signs of aging.
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Tonge, Peter J.
Basak, Sneha
Daryaee, Fereidoon
Abrégé
The invention provides a compound having the structure:
The invention provides a compound having the structure:
wherein R1 and R2 are each independently H, halogen, —NO2, —CN, —NHR14, —NR14R15, —SR14, —SO2R14, —OR14, —CO2R14, —CF3, -alkyl-NR14R15, -alkyl-OR14, C1-10 alkyl, C2-10 alkenyl, or C2-10 alkynyl; or wherein R1 and R2 together formed into a cycloalkyl or cycloheteroalkyl;
wherein R3 and R7 are each independently H, halogen, —NO2, —CN, —NHR14, —NR14R15, —SR14, —SO2R14, —OR14, —CO2R14, —CF3, -alkyl-NR14R15, C1-10 alkyl, C2-10 alkenyl or C2-10 alkynyl;
wherein R4 and R6 are each independently H, —NO2, —SR14, —SO2R14, —OR14, —CO2R14, -alkyl-NR14R15, -alkyl-OR14, C2-10 alkenyl or C2-10 alkynyl;
wherein R5 is —NO2, —NHR14, —NR14R15, —SR14, —SO2R14, —(C═O)—NH—R14, —CO2R14, -alkyl-NR14R15, -alkyl- OR14, C2-10 alkenyl, C2-10 alkynyl, —(C0-10 alkyl)-heterocyclyl,
The invention provides a compound having the structure:
wherein R1 and R2 are each independently H, halogen, —NO2, —CN, —NHR14, —NR14R15, —SR14, —SO2R14, —OR14, —CO2R14, —CF3, -alkyl-NR14R15, -alkyl-OR14, C1-10 alkyl, C2-10 alkenyl, or C2-10 alkynyl; or wherein R1 and R2 together formed into a cycloalkyl or cycloheteroalkyl;
wherein R3 and R7 are each independently H, halogen, —NO2, —CN, —NHR14, —NR14R15, —SR14, —SO2R14, —OR14, —CO2R14, —CF3, -alkyl-NR14R15, C1-10 alkyl, C2-10 alkenyl or C2-10 alkynyl;
wherein R4 and R6 are each independently H, —NO2, —SR14, —SO2R14, —OR14, —CO2R14, -alkyl-NR14R15, -alkyl-OR14, C2-10 alkenyl or C2-10 alkynyl;
wherein R5 is —NO2, —NHR14, —NR14R15, —SR14, —SO2R14, —(C═O)—NH—R14, —CO2R14, -alkyl-NR14R15, -alkyl- OR14, C2-10 alkenyl, C2-10 alkynyl, —(C0-10 alkyl)-heterocyclyl,
wherein R8, R9, R10, and R11 are each independently N or CH;
wherein R12 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalky, or heterocyclyl;
wherein R13 is halogen, —NO2, —CN, —NHR14, —NR14R15, —SR14, —SO2R14, —OR14, —CO2R14, —CF3, —NR14R15, —OR14, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, cycloalkyl, cycloheteroalky, or heterocyclyl;
wherein R14 is H, C2-10 alkenyl, C2-10 alkynyl, —C═O-alkyl-aryl, or alkyl-aryl;
wherein R15 is H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, —C═O-alkyl-aryl, or alkyl-aryl;
wherein X is CH2 or NH;
wherein R3 and R5 are not both halogen, R5 and R7 are not both halogen;
wherein when R3 or R7 is halogen, R4 and R6 are not alkyl;
wherein when R5 is —(C0-10 alkyl)-heterocyclyl, the heterocyclyl is not tetrahydropyranyl;
wherein when R3 or R7 is halogen, R4 and R6 are not —OR14;
wherein when R3 is alkyl or H, R6 is not —NHR14 and —NR14R15; wherein when R7 is alkyl or H, R4 is not —NHR14 and —NR14R15.
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
C07D 213/64 - Un atome d'oxygène lié en position 2 ou 6
C07D 249/06 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
C07D 401/10 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
9.
IMMUNOSTIMULANT-CYTOTOXIC CONJUGATE COMPOSITION AND METHODS FOR CANCER TREATMENT
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Meimetis, Labros
Boros, Eszter
Abrégé
Provided herein are compounds and compositions for the treatment of diseases or conditions such as cancer. Also provided herein methods of treating diseases and conditions and methods of making compounds and compositions.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Bodoin, Emilie
Sadoway, Donald R.
Whittingham, M. Stanley
Lee, Krystal J.
Siu, Carrie
Xin, Fengxia
Abrégé
In some aspects, the present disclosure provides a lithium metal battery having a negative electrode that comprises a substantially pure lithium metal and a positive electrode that comprises the epsilon polymorph of vanadyl phosphate (ε-VOPO4). The lithium metal can have less than five ppm of non-metallic elements by mass. The ε-VOPO4 can be made from solvothermally synthesized H2VOPO4, and be optimized to reversibly intercalate two Li-ions to reach full theoretical capacity with a coulombic efficiency of 98%. This material can adopt a stable 3D tunnel structure and can extract two Li-ions per vanadium ion, giving a theoretical capacity of 305 mAh/g, with an upper charge/discharge plateau at around 4.0 V, and one lower at around 2.5 V. The ε-VOPO4 particles may be modified with niobium (Nb) to improve the cycling stability.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
QUNNECT, INC. (USA)
Inventeur(s)
Figueroa, Eden
Namazi, Mehdi
Flament, Mael
Gera, Sonali
Abrégé
Quantum network devices, systems, and methods are provided to enable long-distance transmission of quantum bits (qubits) for applications such as Quantum Key Distribution (QKD), entanglement distribution, and other quantum communication applications. Such systems and methods provide for separately storing first, second, third, and fourth photons, wherein the first and second photons and the third and fourth photons are respective first and second entangled photon pairs, triggering a synchronized retrieval of the stored first, second, third, and fourth photons such that the first photon is propagated to a first node, the second and third photons are propagated to a second node, and the fourth photon is propagated to a third node, and creating a new entangled pair comprising the first and fourth photons at the first and third nodes to transmit quantum information.
G01B 9/02017 - Interféromètres caractérisés par la configuration du parcours du faisceau avec plusieurs interactions entre l’objet ciblé et les faisceaux lumineux, p. ex. les réflexions des faisceaux provenant de positions différentes
C07J 43/00 - Stéroïdes normaux ayant un hétérocycle contenant de l'azote non condensé ou condensé en spiro avec le squelette du cyclopenta[a]hydrophénanthrène
C07J 3/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par un atome de carbone
A61K 31/567 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en position 17 alpha, p. ex. mestranol, noréthandrolone
A61K 31/06 - Phénols le noyau aromatique étant substitué par des groupes nitro
13.
ANTI-CAMPTOTHECIN ANTIBODIES AND ANTIBODY FRAGMENTS
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Balthasar, Joseph
Bordeau, Brandon
Nguyen, Toan
Abrégé
Provided are compositions and methods for reducing off-target toxicity of antibody-drug conjugates (ADCs). The compositions comprise an ADC, and an agent targeted to the drug (payload) that is delivered by or derived from the ADC. The ADC and the agent targeted to the payload may be delivered together or separately in the treatment of various conditions (such as tumors) by ADCs. Examples of agents targeted to payload include antibodies, fragments, or modifications thereof.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
14.
PIM KINASE INHIBITORS FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AND FIBROSIS ASSOCIATED WITH CANCER
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Foulks, Jason Marc
Warner, Steven L.
Mohi, Golam
Abrégé
Methods for treatment of myeloproliferative neoplasms and/or fibrosis associated with cancer are provided. The disclosed methods comprise administering a PIM kinase inhibitor, and optionally a JAK kinase inhibitor or other therapeutic agent, to a mammal in need thereof.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Khan, Fazel
Bielski, Michael
Khan, Jafar
Kao, Imin
He, Guangyu
Abrégé
A surgical system is provided. The surgical system includes a camera operable to capture images and/or video. A projector is operable to project light, and a controller is communicatively coupled with the camera and the projector. The controller is operable to track movement of bone in real-time during surgery based on the images and/or video captured by the camera, and control the projector to project the light including a cutting line on the bone to indicate a cutting plane for cutting the bone during surgery.
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 90/30 - Dispositifs pour éclairer une zone chirurgicale, les dispositifs ayant une corrélation avec d’autres dispositifs chirurgicaux ou avec une intervention chirurgicale
A61B 90/96 - Moyens d’identification pour les patients ou les instruments, p. ex. étiquettes utilisant des symboles, p. ex. du texte utilisant des codes-barres
16.
POLYMERIC VENOUS VALVE SYSTEMS AND METHODS OF MAKING AND USING THEREOF
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Slepian, Marvin J.
Bluestein, Danny
Kovarovik, Brandon
Abrégé
Polymeric venous valve systems having a supportive frame embedded in a polymeric sleeve and a plurality of polymeric leaflets forming a continuum with the polymeric sleeve are described herein. Methods of making and using such polymeric venous valve systems are also described. The polymeric venous valve systems are well-suited for use in low pressure and low shear venous environments.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Maloney, Lauren M.
Walker, Griffin
Vijaya Kumar, Thea M.
Mertz, Alexander E.
Hebert, Daniella R.
Kupec, Taelyn
Reagan, Sean
Eichert, Alexander J.
Abrégé
A point-of-care ultrasonography (POCUS) training system, method, terminal which may be used in a mobile environment such as a moving vehicle. The system is configured to compensate for the moving of the moving vehicle when determining an orientation of a probe with respect to a target. After the compensated orientation of the probe is determined, the system may select and display an ultrasound image from among a plurality of images. The selected image corresponds to the determined orientation of the probe and a position of the probe with respect to the target, which is based on a pressure sensor system using a flexible pressure map positioned on the target, where a distal tip of the probe is pressed on the target via the flexible pressure map.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Gopalan, Kartik
Yang, Ping
Fernando, Dinuni K.
Terner, Jonathan
Abrégé
Post-copy is one of the two key techniques (besides pre-copy) for live migration of virtual machines in data centers. Post-copy provides deterministic total migration time and low downtime for write-intensive VMs. However, if post-copy migration fails for any reason, the migrating VM is lost because the VM's latest consistent state is split between the source and destination nodes during migration. PostCopyFT provides a new approach to recover a VM after a destination or network failure during post-copy live migration using an efficient reverse incremental checkpointing mechanism. PostCopyFT was implemented and evaluated in the KVM/QEMU platform. Experimental results show that the total migration time of post-copy remains unchanged while maintaining low failover time, downtime, and application performance overhead.
G06F 11/14 - Détection ou correction d'erreur dans les données par redondance dans les opérations, p. ex. en utilisant différentes séquences d'opérations aboutissant au même résultat
G06F 9/455 - ÉmulationInterprétationSimulation de logiciel, p. ex. virtualisation ou émulation des moteurs d’exécution d’applications ou de systèmes d’exploitation
G06F 11/07 - Réaction à l'apparition d'un défaut, p. ex. tolérance de certains défauts
The Research Foundation for the State University of New York (USA)
The University of North Carolina at Chapel Hill (USA)
Inventeur(s)
Rubin, Clinton
Rubin, Janet
Abrégé
The present invention relates to compositions and methods configured to deliver a stimulus (e.g., a therapeutic agent or a therapeutically beneficial signal) to a cell, tissue, organ, or organism. The stimulus is applied at least twice, and the first and second applications are separated by a rest period in which no further stimulus is actively applied. The rest period is of a duration (e.g., about 1-6 hours) sufficient to provoke an enhanced response to the second stimulus.
A61N 2/02 - Magnétothérapie utilisant des champs magnétiques produits par des bobines, y compris par des boucles à spire unique ou par des électro-aimants
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61N 1/05 - Électrodes à implanter ou à introduire dans le corps, p. ex. électrode cardiaque
A61N 1/32 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Schiffres, Scott N.
Azizi, Arad
Abrégé
A cooling device for electronics created ed by additive manufacturing directly on the surface of an electronic device, the colling device created by processes such as controlled focused energy of laser or electron beam, stereolithography, or fused deposition modeling. The cooling device is especially useful in being placed next to or packaged with high-power electronic chips requiring significant heat dissipation.
B22F 7/08 - Fabrication de couches composites, de pièces ou d'objets à base de poudres métalliques, par frittage avec ou sans compactage de pièces ou objets composés de parties différentes, p. ex. pour former des outils à embouts rapportés avec une ou plusieurs parties non faites à partir de poudre
B22F 10/14 - Formation d’un corps vert par projection de liant sur un lit de poudre
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
B29L 31/34 - Appareils électriques, p. ex. bougies ou leurs parties constitutives
Board of Regents, The University of Texas System (USA)
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Vogelstein, Bert
Kinzler, Kenneth W.
Cohen, Joshua David
Papadopoulos, Nickolas
Lennon, Anne Marie
Tomasetti, Cristian
Wang, Yuxuan
Netto, Georges Jabboure
Karchin, Rachel
Douville, Christopher
Hanash, Samir
Springer, Simeon
Grollman, Arthur P.
Dickman, Kathleen
Abrégé
Provided herein are methods and materials for detecting and/or treating subject (e.g., a human) having cancer. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of two or more classes of biomarkers are detected. In some embodiments, methods and materials for identifying a subject as having cancer (e.g., a localized cancer) are provided in which the presence of member(s) of at least one class of biomarkers and the presence of aneuploidy are detected. In some embodiments, methods described herein provide increased sensitivity and/or specificity in the detection of cancer in a subject (e.g. a human).
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Pisconti, Addolorata
Abrégé
The invention provides anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopa-thy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. By protecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/222 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine avec des composés ayant des groupes aromatiques, p. ex. dipivéfrine, ibopamine
A61K 31/26 - Esters d'acide cyanique ou isocyaniqueEsters d'acide thiocyanique ou isothiocyanique
A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p. ex. chorée, dyskinésie
24.
ANTIBODY-DRUG COMPLEXES WITH TOPOISOMERASE INHIBITORS
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Tumey, Lawrence Nathan
Ojo, Victor
Bianchi, Nicholas
Abrégé
Disclosed herein are antibody-drug-conjugates (ADC) that allow for delivery and release of topoisomerase inhibitors into desired tissues. The disclosed ADCs include an AsnAsn peptide that facilitates the release of an exatecan derivative by legumain. The antibody-drug-conjugates are useful as therapeutic agents for treating various cancers. Pharmaceutical compositions which include the ADCs are also disclosed, as are methods of treating a tumor or abnormal cell proliferation by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein under conditions effective to treat a tumor or abnormal cell proliferation.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Balthasar, Joseph
Bordeau, Brandon
Nguyen, Toan Duc
Abrégé
Provided are binding partners that specifically bind to erythrocyte protein SLC4A1 transporter (Band 3) that is highly expressed on erythrocytes. The binding partners are provided as single-specific, bi- specific or multi-specific agents that have improved half-life and/or are effective at a lower concentration. A second component of a bispecific binding partner can bind to a payload-binding selectivity enhancer (PBSE), such as a drug that has been detached from an anti-body drug conjugate. In non-limiting embodiments the PBSE specifically binds to a drug that was administered to an individual as a component of an ADC.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Ju, Jingfang
Ojima, Iwao
Yuen, John
Chen, Lei
Abrégé
The present disclosure provides double-stranded nucleic acid compositions that incorporate uracil, gemcitabine, and methotrexate (MTX). More specifically, the present disclosure reveals that the modifications of double-stranded micro-RNA nucleotide sequences with 5-fluorouracil, gemcitabine and methotrexate (MTX) enhance the therapeutic efficacy of tumor suppression and tumor specificity. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-fluorouracil, gemcitabine and methotrexate (MTX) incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancers, such as pancreatic cancer. This is a platform technology that can be applied to other tumor suppressor miRNAs as well as siRNAs.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7064 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées
A61K 31/7115 - Acides nucléiques ou oligonucléotides ayant des bases modifiées, c.-à-d. autres que l'adénine, la guanine, la cytosine, l'uracile ou la thymine
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Toyota Motor Engineering & Manufacturing North America, Inc. (USA)
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Zhou, Yuqing
Tanaka, Masato
Song, Yuyang
Gu, Xianfeng David
Chen, Shikui
Zhao, Zhou
Gao, Lingfeng
Abrégé
Systems, methods, and other embodiments described herein relate to multiple three-dimensional (3D) structures formation from a network of circularly-packed structural elements. In one embodiment, a system includes a circularly-packed network of structural elements that form multiple 3D structures. Diameters of the structural elements define a shape of the 3D structures. The circularly-packed network is adaptable to form 1) a first 3D structure and 2) a second 3D structure with a different shape than the first 3D structure. The system also includes a set of joints that connect adjacent structural elements.
The Research Foundation for The State University of new York (USA)
Inventeur(s)
Ghose, Kanad
Abrégé
A system and method of scheduling tasks, comprising receiving activity and performance data from registers or storage locations maintained by hardware and an operating system; storing calibration coefficients associated with the activity and performance data; computing an energy dissipation rate based on at least the activity and performance data; and scheduling tasks under the operating system based on the computed energy dissipation rate.
B03B 1/00 - Traitement pour faciliter la séparation, en altérant les propriétés physiques du matériau à traiter
B03B 5/02 - Lavage de matériaux en grains, en poudre ou en grumeauxSéparation par voie humide en utilisant comme moyens principaux de séparation, des lits secoués, pulsés ou agités
B03B 5/58 - Classificateurs du type à coupe, c.-à-d. à râteaux rotatifs et extraction
B03B 11/00 - Dispositifs d'alimentation ou d'évacuation intégrés dans un matériel de lavage ou de séparation par voie humide
G05D 23/19 - Commande de la température caractérisée par l'utilisation de moyens électriques
G06F 1/3203 - Gestion de l’alimentation, c.-à-d. passage en mode d’économie d’énergie amorcé par événements
G06F 1/3206 - Surveillance d’événements, de dispositifs ou de paramètres initiant un changement de mode d’alimentation
G06F 1/3228 - Surveillance d’exécution de tâches, p. ex. par utilisation de temporisations d’attente, de commandes d’arrêt ou de commandes d’attente
G06F 9/455 - ÉmulationInterprétationSimulation de logiciel, p. ex. virtualisation ou émulation des moteurs d’exécution d’applications ou de systèmes d’exploitation
G06F 9/48 - Lancement de programmes Commutation de programmes, p. ex. par interruption
G06F 9/50 - Allocation de ressources, p. ex. de l'unité centrale de traitement [UCT]
G06K 19/07 - Supports d'enregistrement avec des marques conductrices, des circuits imprimés ou des éléments de circuit à semi-conducteurs, p. ex. cartes d'identité ou cartes de crédit avec des puces à circuit intégré
G06K 19/077 - Détails de structure, p. ex. montage de circuits dans le support
H04L 69/329 - Protocoles de communication intra-couche entre entités paires ou définitions d'unité de données de protocole [PDU] dans la couche application [couche OSI 7]
H05K 7/20 - Modifications en vue de faciliter la réfrigération, l'aération ou le chauffage
29.
ORAL COMPOSITIONS AND METHODS OF REDUCING ORAL MALODOR
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Cohen, Marvin
Cohen, Susanne
Flynn, Robert
Abrégé
Oral compositions and methods of reducing oral malodor are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound and a pharmaceutically acceptable carrier; and further comprises essential oil.
A61K 8/36 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 8/368 - Acides carboxyliquesLeurs sels ou anhydrides dans lesquels le groupe carboxyle est directement lié aux atomes de carbone du cycle aromatique
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
A61K 8/92 - Huiles, graisses ou ciresLeurs dérivés, p. ex. produits d'hydrogénation
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/4425 - Dérivés de pyridinium, p. ex. pralidoxime, pyridostigmine
A61K 33/20 - Chlore élémentaireComposés minéraux libérant du chlore
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Zhang, Peng
Feng, Fei
Zhou, Yifan
Tang, Zefan
Abrégé
A method of performing state estimation for a microgrid system includes: obtaining a general quantum state estimation model for swing-bus-contained microgrid systems; establishing a state estimation formulation through quantum language; assigning quantum registers used during a quantum state estimation iteration; generating a quantum-circuit-based state estimation solver for performing quantum phase estimation, controlled rotation, and inverse quantum phase estimation; generating a preconditioned quantum linear solver for an ill-conditioned state estimation iteration; iteratively optimizing voltage and residual vectors while iteratively updating preconditioned errors by the state estimation solver, the optimizing and updating iterations continuing until the linear solver reaches convergence; obtaining a quantum state estimation model for hierarchical-based microgrid systems including droop and/or secondary control modes; establishing an enhanced quantum state estimation framework including the state estimation solver and the linear solver; and generating an enhanced state estimation output for controlling one or more parameters of the microgrid system.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSTIY OF NEW YORK (USA)
Inventeur(s)
Sung, Woongje
Abrégé
A field effect transistor includes first section and second sections. The first section includes a drift layer. A first P-well is disposed over the drift layer. A first N-source is disposed over the first P-well. A first channel is disposed in an upper portion of the first P-well. The second section includes an area P-well disposed within the drift layer and formed integral with the first P-well. The area P-well includes sidewalls that extend upwards from the drift layer to form an enclosed structure with an outer perimeter and an inner perimeter. An area N-source surrounds the outer perimeter and is formed integral with the first N-source. An upwardly extending intermediate portion of the drift layer extends upwards though the inner perimeter. A second channel is disposed in an upper portion of the sidewalls and is bounded by the inner perimeter and outer perimeter of the sidewalls.
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 21/04 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives les dispositifs ayant des barrières de potentiel, p. ex. une jonction PN, une région d'appauvrissement ou une région de concentration de porteurs de charges
H01L 29/08 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices avec des régions semi-conductrices connectées à une électrode transportant le courant à redresser, amplifier ou commuter, cette électrode faisant partie d'un dispositif à semi-conducteur qui comporte trois électrodes ou plus
H01L 29/16 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, mis à part les matériaux de dopage ou autres impuretés, seulement des éléments du groupe IV de la classification périodique, sous forme non combinée
H01L 29/66 - Types de dispositifs semi-conducteurs
H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
32.
COMPOSITIONS AND METHODS FOR ANALYTE DETECTION USING NANOSWITCHES
The Research Foundation for The State University of New York (USA)
Children's Medical Center Corporation (USA)
Inventeur(s)
Chandrasekaran, Arun Richard
Hansen, Clinton H.
Koussa, Mounir Ahmad
Halvorsen, Kenneth Anders
Wong, Wesley Philip
Abrégé
Provided herein are nucleic acid-based nanoswitches that can detect specific nucleic acids and other analytes types by for example a simple gel electrophoresis readout. Binding of the target to the nanoswitches induces a conformation change from a linear, open conformation to a looped, closed conformation. These nanoswitches may be used in diagnostic assays such as nucleic acid-based diagnostic assays, to detect, measure and/or purify a variety of targets including low abundance targets.
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p. ex. transfert d’énergie de résonance
C12Q 1/6839 - Formation de chaine hélicoïdale triple ou autres conformations supérieures dans les tests d’hybridation
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
TRUSTEES OF DARTMOUTH COLLEGE (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Strey, Lilianne R.
Strey, Helmut
Granger, Richard M.
Edelman, Alan
Rackauckas, Christopher
Miller, Earl K.
Abrégé
A system for generation and execution of brain circuit simulators includes at least one modular, hierarchical design comprising a plurality of micro-circuits. The system includes a neural control circuit simulator executing a simulation of the at least one design. The system includes a user interface comprising at least one interface element for manipulating output of the neural control circuit simulator. A method includes receiving, by a neural control circuit simulator, an identification of at least one modular, hierarchical design comprising a plurality of micro-circuits, the at least one modular, hierarchical design generated by a first user. The neural control circuit simulator executes a first simulation of the at least one design, using a first data set as simulation input. The neural control circuit simulator receives a second data set and executes a second simulation of the at least one modular, hierarchical design, using the second data set as simulation input.
G06N 3/10 - Interfaces, langages de programmation ou boîtes à outils de développement logiciel, p. ex. pour la simulation de réseaux neuronaux
G06N 3/063 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
34.
LITHOGRAPHY COMPOSITIONS AND METHODS FOR FORMING RESIST PATTERNS AND/OR MAKING SEMICONDUCTOR DEVICES
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Ali, Munsaf
Brainard, Robert
Abrégé
The present disclosure relates to compounds and use thereof as lithographic compositions such as EUV photoresist films. More particularly, embodiments of the disclosure provide lithography compositions and methods of depositing radiation sensitive films, which can be used for patterning applications with UV light, EUV light or electron-beam radiation to form high resolution patterns with low line width roughness. In embodiments, novel ligands are provided for forming radiation sensitive film compositions.
The Research Foundation for The State University of new York (USA)
Inventeur(s)
Nikulin, Alex
De Smet, Timothy S.
Abrégé
There are approximately 35,000 abandoned and unplugged oil and gas wells in New York with no known location. Unplugged wells emit methane, a strong greenhouse gas, which has the potential to significantly contribute to global climate change and act as a pollutant chemical. A long-range UAV equipped with methane sensors, MagPike (atomic magnetometer), and LiDAR sensors successfully detected unmarked well sites using characteristic magnetic signals generated by vertical metal piping preserved in the ground. The optimal flight altitude and transect spacing was determined for detection driven by the total field strength of the Earth's magnetic field and the height of tree canopies determined by LiDAR. Traditional methods of identifying oil and gas wells are costly and less powerful in acquisition of data such as using large magnetometers attached to helicopters.
B64U 101/00 - Véhicules aériens sans pilote spécialement adaptés à des utilisations ou à des applications spécifiques
B64U 101/30 - Véhicules aériens sans pilote spécialement adaptés à des utilisations ou à des applications spécifiques à l’imagerie, à la photographie ou à la vidéographie
G01S 19/40 - Correction de position, de vitesse ou d'attitude
G05D 1/606 - Compensation ou utilisation des conditions ambiantes externes, p. ex. du vent ou des courants d’eau
36.
RISK ADJUSTED MORTALITY RATE USING AUTOMATED DETERMINATION OF PATIENT CO-MORBIDITIES
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Ramakrishnan, I.V.
Henry, Mark
Abrégé
Systems and methods for decreasing risk-adjusted mortality rates, including identifying patient co-morbidity-related clinical data by preprocessing historical patient data based on rules. Identified co-morbidity-related clinical data is displayed using an interactive user interface for validation, and validated results are stored in an electronic health record (EHR) for the patient. Updated co-morbidity-related clinical is identified by concurrent processing updated patient data based on the rules. The updated co-morbidity-related clinical data is displayed using the interactive user interface for further validation. The EHR is iteratively updated with revised co-morbidity data by the postprocessing upon detection of changes to the EHR.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
37.
SYSTEM AND METHOD FOR ANALYSIS OF EARWAX LIPID PROFILE FOR DISEASE DIAGNOSIS
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Musah, Rabi
Coon, Allix
Setzen, Gavin
Abrégé
A system and method for analyzing a sample of earwax for chemical components indicating the presence of an otolaryngological disorder, such as Meniere's Disease. The system includes an analyzer that receives an earwax sample from a person, where the analyzer analyzes the earwax sample and produces diagnostic data. The diagnostic data includes chemical component data for the earwax sample and there is a computer device in communication with analyzer, and the computer device receives the diagnostic data from the analyzer and detects a predetermined combination of chemical components in the earwax sample which will indicate the presence of an otolaryngological disorder.
G01N 30/88 - Systèmes intégrés d'analyse, spécialement adaptés à cet effet, non couverts par un seul des groupes
G01N 33/483 - Analyse physique de matériau biologique
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
38.
Adeno-Associated-Virus Rep Sequences, Vectors and Viruses
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Bahou, Wadie F.
Hearing, Patrick
Sitaraman, Varsha
Abrégé
The invention provides adeno-associated virus (AAV) replication (Rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type AAV Rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type AAV Rep inhibitory amino acid sequence. The invention provides vectors, cells, and viruses containing the invention's sequences. Also provided are methods for detecting portions of the AAV Rep inhibitory amino acid sequence, which reduce replication and/or infection and/or productive infection by viruses. The invention's compositions and methods are useful for site-specific integration and/or expression of heterologous sequences by recombinant adeno-associated virus (rAAV) vectors and by rAAV virus particles, such as hybrid viruses (e.g., Ad-AAV) comprising such vectors. The invention's compositions and methods find application in, for example, gene therapy and/or vaccines.
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
39.
HIGH-TEMPERATURE MOLTEN SALTS STRUCTURE ANALYSIS SYSTEM
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Khaykovich, Boris
Zheng, Guiqiu
Sprouster, David
Abrégé
A system for determining atomic structure and dynamics of salt under certain temperatures as a function of temperature above and below salt melting, contains a quartz tube containing a first end and a second end, and a graphite rod that is located within the quartz tube. The graphite rod contains a hollow center that extends from a top portion of the rod to a location prior to a bottom of the rod, wherein the bottom portion of the rod is enclosed. A sample of salt is located within the hollow center of the graphite rod. A filling material having the characteristics of not reacting to the graphite rod and not changing state with heating of the salt to a melting point of the salt, and wherein the filling material is positioned beneath the graphite rod between the second end of the quartz tube and the bottom of the graphite rod.
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
G01N 1/44 - Traitement d'échantillons mettant en œuvre un rayonnement, p. ex. de la chaleur
40.
STRUCTURES FOR SOLAR VAPOR EVAPORATION AND CONDENSATION
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Gan, Qiaoqiang
Zhou, Lyu
Abrégé
A solar vapor generation system includes a substrate configured to wick solution from a reservoir. The substrate includes a first planar sheet having a first end, and a second planar sheet having a first end. The first end of the first planar sheet is connected to the first end of the second planar sheet at an angle of less than 180.0 degrees. In some embodiments, the angle is less than 90.0 degrees. At least a portion of the first planar sheet is configured to be in contact with the solution. The system includes a support, configured to support the substrate at a position near a surface of the solution.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Hsiao, Benjamin S.
Sharma, Priyanka
Sharma, Sunil Kumar
Johnson, Ken I.
Abrégé
A method of treating contaminated water, such as wastewater, with carboxylated cellulose to remove ammonium and nitrogen-containing impurities is claimed. Carboxylated cellulose extracted by nitro-oxidation has negatively-charged functionality and forms an aggregate when exposed to positively-charged impurities in contaminated water. The aggregate, nitrogen-containing impurities, and by-products from the nitro-oxidation process can be isolated to provide a fertilizer or fertilizer component.
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
B01J 20/24 - Composés macromoléculaires d'origine naturelle, p. ex. acides humiques ou leurs dérivés
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
C02F 101/16 - Composés de l'azote, p. ex. ammoniac
C05F 7/00 - Engrais fabriqués à partir des eaux résiduaires ou d'épandage, wagage, limon ou masses similaires
42.
ADJUSTING TUNNEL JUNCTION CHARACTERISTICS OF ATOMIC LAYER DEPOSITION FILMS THROUGH UNDERLAYER MODIFICATION
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Borst, Christopher
Frost, Hunter
Bhatia, Ekta
Vo, Tuan
Kar, Soumen
Papa Rao, Satyavolu
Abrégé
A system and method for tuning a high-resistivity layer of TaN deposited by atomic layer deposition (ALD) over a superconducting metal underlayer that has undergone one of a set of treatments. The underlayer can be chosen or modified in such a way to yield an ALD TaN thin film with predictably high- or low-resistivity. A low-resistivity layer of ALD TaN is deposited on exposed metal layers, whether they are superconducting metals or non-superconducting metals, while a high-resistivity layer of ALD TaN is deposited on exposed dielectrics, as well as modified surfaces of exposed metals. This modification may be achieved through the use of a physical vapor deposited (PVD) metal nitride intervening layer, such as PVD TaN and PVD NbN, deposited between the high-resistivity layer and the metal layer.
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Cui, Weili
Miles, Ronald
Cui, Jaron
Abrégé
A microstructure that detects the acoustic velocity of a fluid by employing microfabricated thin sensing elements that are primarily driven by viscous forces due to the fluctuating motion of a fluid, such as air in a sound field. The microstructures can be fabricated in an array to create a diaphragmless microphone. The microstructure and its components can be fabricated on a single or multilayer substrate with the use of masks.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Scheuermann, James
Zhao, Wei
Abrégé
A sensor including a layer of amorphous selenium (a-Se) and at least one charge blocking layer is formed by depositing the charge blocking layer over a substrate prior to depositing the amorphous selenium, enabling the charge blocking layer to be formed at elevated temperatures. Such a process is not limited by the crystallization temperature of a-Se, resulting in the formation of an efficient charge blocking layer, which enables improved signal amplification of the resulting device. The sensor can be fabricated by forming first and second amorphous selenium layers over separate substrates, and then fusing the a-Se layers at a relatively low temperature.
H10K 30/10 - Dispositifs organiques sensibles au rayonnement infrarouge, à la lumière, au rayonnement électromagnétique de plus courte longueur d'onde ou au rayonnement corpusculaire comprenant des hétérojonctions entre des semi-conducteurs organiques et des semi-conducteurs inorganiques
G01T 1/24 - Mesure de l'intensité de radiation avec des détecteurs à semi-conducteurs
H01L 31/0256 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails caractérisés par leurs corps semi-conducteurs caractérisés par les matériaux
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE (USA)
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Collins, Peter L.
Le Nouen, Cyril
Brock, Linda G.
Buchholz, Ursula J.
Dinapoli, Joshua Marc
Mueller, Steffen
Wimmer, Eckard
Abrégé
Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Guo, Dandan
Hossan, Md Shanewaz
Luo, Juntao
Shi, Changying
Abrégé
Disclosed herein are novel well-defined telodendrimer nanodrugs featured with multiple negative charges and hydrophobic groups to mimic endotoxin for toll-like receptor binding, thus to modulate immune response. The next generation TD nanodrugs can actively fine-tuned inflammation control against a broad spectrum of immune stimuli via pleiotropic mechanisms; and some TD nanodrugs can stimulate immune response by activating TLR for potential cancer immunotherapy; as well as TD nanodrugs that can form nanocarrier for the delivery of vital antibiotics, anticancer drugs or other therapeutics for disease treatments with simultaneous immune modulation effects.
47.
BORONATE PRODRUG NANOFORMULATIONS IN DISEASE TREATMENTS
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Guo, Dandan
Luo, Juntao
Shi, Changying
Abrégé
Amphotericin B (AmB) is the gold standard for treatment of life-threatening systemic fungal infections. To develop cost-effective AmB formulations with reduced toxicity, embodiments disclosed introduce controlled number of phenylboronic acid (PBA) moieties into telodendrimer (TD) nanoplatform for optimizing AmB conjugation via reversible boronate ester strategy. This multivalent flexible boronate TD nanoplatform can also be applied in developing prodrugs for different cis-diol containing or α- or β- hydroxyl ketone-containing drug molecules.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Qu, Jun
Abrégé
A tissue sample sectioning device including a supporting matrix having a top surface, configured to accept a tissue sample thereon, a micro-scaffold comprising a top, a bottom, and a plurality of micro-wells, wherein each micro-well is defined by at least one or more walls that extend between the top and the bottom of the micro-scaffold, and each of the one or more walls has a cutting edge at the bottom of the micro-scaffold, and a press configured to apply a force onto the micro-scaffold, such that when a force is applied, the cutting edge cuts the tissue sample, and the tissue sample is sectioned into the plurality of micro-wells. The disclosure also provides a method of sectioning a tissue sample using the supporting matrix and the micro- scaffold by applying a force.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Haney, Neil
Abrégé
A device that fits over the end of a drill bit to enable the user to center the bit over a predetermined location, usually made with a center punch drill rig. The device slips over the end of the drill bit and has a pointed end for locational purposes. The device can be inexpensively manufactured in plastic, aluminum, or steel as needed for durability and cost effectiveness.
B23B 51/12 - Adaptateurs pour forets ou mandrinsDouilles de réduction coniques
B23B 49/00 - Systèmes de mesure ou de calibrage des machines à aléser, pour le positionnement ou le guidage du foretDispositif pour indiquer les défauts des forets pendant l'alésageDispositifs à centrer les trous à aléser
50.
SECURE PROCESSOR FOR DETECTING AND PREVENTING EXPLOITS OF SOFTWARE VULNERABILITY
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Ghose, Kanad
Abrégé
A secure processor, comprising a logic execution unit configured to process data based on instructions; a communication interface unit, configured to transfer of the instructions and the data, and metadata tags accompanying respective instructions and data; a metadata processing unit, configured to enforce specific restrictions with respect to at least execution of instructions, access to resources, and manipulation of data, selectively dependent on the received metadata tags; and a control transfer processing unit, configured to validate a branch instruction execution and an entry point instruction of each control transfer, selectively dependent on the respective metadata tags.
Research Foundation for the State University of New York (USA)
Inventeur(s)
Gopalan, Kartik
Lu, Hui
Abrégé
Systems and methods for live updating virtualization systems are disclosed. One method may include identifying a container on a first virtual machine of a virtualization system. The container may include at least one process associated with performing a task on a first virtual machine. The method may also include determining a first communication path between the process included in the container on the first virtual machine and a hypervisor of the virtualization system, and migrating the container and the process included in the container to a second virtual machine. The second virtual machine may be distinct from the first virtual machine. Additionally, the method may include determining a second communication path between the process included in the migrated container on the second virtual machine and the hypervisor of the virtualization system.
G06F 9/455 - ÉmulationInterprétationSimulation de logiciel, p. ex. virtualisation ou émulation des moteurs d’exécution d’applications ou de systèmes d’exploitation
52.
CHEMICALLY MODIFIED CURCUMINS FOR USE IN THE PRODUCTION OF LIPOXINS
The Research Foundation for the State University of New York (USA)
Chem-Master International Inc. (USA)
Inventeur(s)
Wang, Guirong
Yongan, Xu
Gu, Ying
Lee, Hsi-Ming
Golub, Lorne M.
Johnson, Francis
Xu, Yongan
Abrégé
A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure:
A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure:
A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure:
or a pharmaceutically acceptable salt or ester thereof, so as to thereby increase production of the one or more lipoxins in the subject.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
53.
HIGH THERMAL CONDUCTIVITY, LOW THERMAL EXPANSION COMPOSITES
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Schiffres, Scott N.
Azizi, Arad
Abrégé
Additively manufactured non-metal particle and metal matrix composites are provided. An intermetallic compound interface layer, e.g., metal carbide, is formed between the non-metal particle, e.g., diamond, and the metal matrix, that enhances thermal transfer. One application of this is to form thermal management structures with high thermal conductivity via laser powder bed fusion. A powder material for additively manufacturing a structure, comprising metal particles; and non-metallic particles with thermal conductivities greater than 100 W/m-K and coefficient of thermal expansion less than 10 ppm/degree C., wherein the metal particles are fusible with heat to form a heterogeneous solid structure around the non-metallic particles with an intermetallic compound interface, the heterogeneous solid structure having enhanced thermal conductivity and lower coefficient of thermal expansion with respect to a homogeneous specimen of the fused metal particles alone.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Zhou, Austin
Luo, Fang
Choksi, Kushan
Mirza, Abdul Basit
Hijikata, Masayuki
Abrégé
A digital twin which may be used to determine the health of a power converter, a method for using the digital twin and a health monitoring system is provided. The digital twin may comprise a plurality of state equations representing circuit components of the power converter and at least one associated value for each component. Each state equation is capable of representing the circuit components for a defined power converter topology and related variants. The digital twin also has a self-evolving monitoring function. The self-evolving monitoring function has adjustable model parameters, an adjustable threshold and adjustable determination parameters. The adjustable model parameters may include weights for combining determined voltage and determined current, respectively. The adjustable determination parameters may be used to determine sets of values for the components for predicting the voltage and current, respectively. The method/system is able to, in real-time, determine component degradation in the power converter.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Tumey, Lawrence Nathan
Ojo, Victor
Abrégé
Disclosed herein are antibody-drug-conjugates (ADC) of Formula (A) containing both a toll-like receptor (TER) agonist (immune stimulant) and MMAF or MMAE: (Formula A) The antibody-drug-conjugates are useful as therapeutic agents for treating various cancers. Pharmaceutical compositions which include the ADCs are also disclosed. Also disclosed are methods of treating a tumor or abnormal cell proliferation by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein under conditions effective to treat a tumor or abnormal cell proliferation. Also disclosed are methods for stimulating an immune response and/or inducing an anti -tumor immune response in a subject by administering a therapeutically effective amount of an antibody-drug-conjugate disclosed herein.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
C07D 487/00 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Mcfarland, Jesse M.
Oneto, José Manuel Mejía
Cabrera-Pardo, Jaime R.
Royzen, Maksim
Saadiq, Muhammad
Abrégé
The present disclosure relates generally to trans-cyclooctene-modified TPD conjugate comprising a targeted protein degrader (TPD) covalently bonded to at least one trans-cyclooctene moiety, optionally via a linker, which conjugates have applications, e.g., in the treatment of cancer, tumor growth, and immunotherapy.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Sheng, Jia
Wang, Rui
Abrégé
Provided is provided is a compound of Formula I
Provided is provided is a compound of Formula I
Provided is provided is a compound of Formula I
and a method of forming a tagged 2-thiouridine tRNA by contacting it with a compound of Formula I, wherein the compound may include a label such as a fluorescent label. Also provided is a method of forming a tagged RNA, comprising contacting a prenylated tRNA or an N6-isopentenyladenosine-prenylated RNA with a 4-phenyl-1,2,4-triazoline-3,5-dione activated fluorescence label. Also provided is a method of sequencing a polyribonucleotide comprising a prenyl group.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
58.
IgA MONOCLONAL ANTIBODIES FOR TREATING FLAVIVIRUS INFECTION
The Research Foundation for the State University of New York (USA)
THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (USA)
Inventeur(s)
Waickman, Adam
Wegman, Adam
Currier, Jeffrey
Friberg, Heather
Mccracken, Michael
Gromowski, Gregory
Abrégé
The present disclosure relates to IgA antibodies and antigen binding fragments thereof and to cocktails of antibodies and antigen binding fragments that neutralize virus infection without contributing to antibody-dependent enhancement of dengue virus infection. The present disclosure also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antigen binding fragments.
The Research Foundation for the State University of New York (USA)
SYRACUSE UNIVERSITY (USA)
Inventeur(s)
Kerr, William
Pedicone, Chiara
Chisolm, John
Dormann, Shawn
Abrégé
The present disclosure provides methods of using compositions that inhibit SII2-containing inositol 5′-phosphatases (SHIPs) for activating microglial cells, as well as methods for using such compositions for treatment or ameliorating of neurodegenerative disorders in a subject.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone
A61K 31/5685 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p. ex. androstane, testostérone ayant un groupe oxo en position 17, p. ex. androstérone
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
60.
NATIVE PEPTIDE CYCLIZATION, SEQUENTIAL CHEMOSELECTIVE AMIDATION IN WATER
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Zhang, Qiang
Chen, Huan
Abrégé
Disclosed herein are processes directed to Native Peptide Cyclization (NPC) and chemoselective methods enabling intramolecular and intermolecular peptidyl ligation without the need for premodification of starting peptides. NPC cyclizes unprotected linear peptides through controlled, sequential C- and N-terminal NPC simplifies peptide ligation, easing the labor-intensive nature of peptide synthesis, efficient cyclic peptide preparation and enabling cost-effective macrocycle-based therapeutics.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Thomas, Christopher
Scheel, Ryan
Ramarao, Bandaru
Nomura, Christopher
Kumar, Deepak
Abrégé
The present disclosure provides a microorganism and expression cassette useful for biologically producing PHA ho-mopolymers and/or PHA copolymers, including PHB-co-MCL copolymers of controllable or predetermined composition. In embodiments, the present disclosure provides a nucleic acid construct suitable for use in a microorganism and/or expression cassette including a nucleic acid construct including: one or more genes comprising a phaJ4 gene, a phaA gene, a phaB gene, a phaC1 gene, or combinations thereof; a cDNA that encodes one or more proteins comprising an enoyl-CoA hydratase 2, a β-ketothiolase, an acetoacetyl-CoA reductase, a type II poly hydroxyalkanoate synthase, or combinations thereof; or one or more nucleic acid sequences that encode one or more proteins including an enoyl-CoA hydratase 2, a β-ketothiolase, an acetoacetyl-CoA reductase, a type II poly hydroxyalkanoate synthase, or combinations thereof.
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Hsiao, Benjamin, S.
Johnson, Ken, I.
Das, Rasel
Ilacas, Grenalynn, C.
Abrégé
The present disclosure provides methods for treating biowaste and similar waste sources with nitric acid. Where the waste source includes plant-based fibrous materials, animal and food waste, the present methods provide for the extraction and use of nanostructured cellulose (nanocellulose) with an anionic surface charge for adsorption of cationic contaminants such as ammonium, and selective environmentally friendly methods for the functionalization of cellulosic biomass.
B09B 3/00 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif
B09B 3/40 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif impliquant un traitement thermique, p. ex. évaporation
C05F 17/50 - Procédés combinant au moins deux traitements différents biologiques ou biochimiques, p. ex. des traitements anaérobie et aérobie ou lombricompostage et traitement aérobie
C05F 9/00 - Engrais fabriqués à partir des ordures ménagères ou de ville
63.
ARTIFICIAL INTELLIGENCE SYSTEM FOR TUMOR DIAGNOSTICS OF CLINICAL MAGNETIC RESONANCE IMAGING DATASETS
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Paluh, Janet
Chatterjee, Ayan
Mukherjee, Amitava
Abrégé
A deep-learning artificial intelligence (AI) framework that applies neuromorphic analysis to complex clinical MRI DICOM datasets to enable typing of brain tumors that are glioblastomas or of metastatic origin with high accuracy. The data processing is optimized to address MRI modality class imbalance, remove lack of comparability, and aid generalizability to create a computationally light, portable, highly accurate and reliable diagnosis platform. The present AI capabilities to continue learning from complex and diverse clinical MRI datasets brings MRI robustness in biomedical neurosurgical treatment pre-planning, with applications in other brain pathologies and expanded use in artificial generalizable intelligence.
G06N 5/04 - Modèles d’inférence ou de raisonnement
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Efstathiadis, Haralabos
Gherasoiu, Iulian
Kumaran, Yamini
Abrégé
A system and method for producing a flattened and smoothed metallic wafer using a top pressure tool plate and a bottom pressure tool plate with a first pressure application device in physical contact with the top pressure tool plate and a second pressure application device in physical contact with the bottom pressure tool plate. A first semiconductor wafer in is selective contact with the top pressure tool plate and a second semiconductor wafer is in selective contact with the bottom pressure tool plate, with a metallic wafer held between the first semiconductor wafer and second semiconductor wafer. The first and second semiconductor wafers can be Si wafers. A predetermined amount of pressure is applied for a predetermined duration from the top pressure tool plate and bottom pressure tool plate with the first pressure application device and second pressure application device to flatten and smooth the metallic wafer.
B21D 39/03 - Utilisation de procédés permettant d'assembler des objets ou des parties d'objets, p. ex. revêtement par des tôles, autrement que par placageDispositifs de mandrinage des tubes des tôles autrement que par pliage
65.
ABI1 REGULATES TRANSCRIPTIONAL ACTIVITY OF ANDROGEN RECEPTOR BY NOVEL DNA AND AR BINDING MECHANISM
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Kotula, Leszek
Bah, Alaji
Frueh, Dominique
Abrégé
The embodiments disclosed herein are directed to identifying novel mechanisms of transcription in prostate cancer by a unique DNA binding mechanism involving actin cytoskeleton regulatory protein ABI1. Further embodiments disclosed herein are directed to ABI1-DNA binding activities that predict survival of prostate cancer patients. Moreover, the embodiments disclosed herein are directed to ABI1-AR reciprocal regulation that has far reaching implications for tumor plasticity and androgen-sensitive pathogenesis.
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Liang, Yanna
Zhang, Weilan
Abrégé
A method for enhanced phytoremediation by changing bioavailability of per- and polyfluoroalkyl substances (PFAS) to plants in biosolids amended soil through stabilization or mobilization. A mobilizing reagent can be added at a predetermined dose, to amend the soil around a root system of one or more plants, and the amended soil can also be supplemented with a stabilizing reagent at a predetermined dose to change the bioavailability of (PFAS) to one or more plants in the amended soil. Through adjustment of the mobilizing reagent and stabilizing reagent, the uptake of PFAS by the one or more plants can be selectively increased or decreased.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Ren, Shenqiang
Di Luigi, Massimigliano
Abrégé
A method for forming a ceramic aerogel includes contacting a ceramic precursor, an additive, an anionic surfactant, a cationic surfactant, and a catalyst to form a mixture. The catalyst may include an acid or a base. The method further includes heating the mixture to form a precursor gel, mixing fibers with the precursor gel, and drying the resultant fiber containing precursor gel.
C04B 35/14 - Produits céramiques mis en forme, caractérisés par leur compositionCompositions céramiquesTraitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base d'oxydes à base de silice
C04B 38/00 - Mortiers, béton, pierre artificielle ou articles de céramiques poreuxLeur préparation
C04B 38/02 - Mortiers, béton, pierre artificielle ou articles de céramiques poreuxLeur préparation par addition d'agents chimiques gonflants
68.
ANION-BINDING AROMATIC OLIGOAMIDE MACROCYCLES AND METHODS OF MAKING AND USING SAME
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Gong, Bing
Cao, Ruikai
Abrégé
Provided are compounds having the following structure: (I) or (II) The compounds may be used to sequester one or more hydrogen-bond acceptors and/or ions. Also provided are methods for making the compounds and methods for using the compounds for treating individuals diagnosed with or suspected of having an extracellular and/or intracellular anion imbalances and/or cystic fibrosis.
C07D 259/00 - Composés hétérocycliques contenant des cycles comportant plus de quatre atomes d'azote comme uniques hétéro-atomes du cycle
C07C 237/28 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné
C07C 237/42 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant l'atome de carbone d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons non condensé du squelette carboné ayant des atomes d'azote de groupes amino liés au squelette carboné de la partie acide, en outre acylés
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
C07D 209/56 - Systèmes cycliques contenant au moins trois cycles
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Andreadis, Stelios
Mohamed, Mohamed Alaa
Abrégé
The present disclosure is directed to shear-thinning and stabilizing hydrogels, especially for use in drug delivery, therapy, and 3D printing. Embodiments provide an injectable hydrogel, including: a water-soluble polymer including a first functional group; a host molecule including a second functional group, wherein the second functional group is characterized as complementary to the first functional group; and a guest-terminated star polymer, wherein the guest-terminated star polymer comprises a core unit, a plurality of arms extending from the core unit, and a guest molecule disposed at a terminal end of each of the plurality of arms, and wherein the host molecule and the guest-terminated star polymer are linked by one or more bonds that break under mechanical stress and reform after removal of the mechanical stress.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
70.
CURCUMIN ANALOGUES AS ZINC CHELATORS AND THEIR USES
The Research Foundation for the State University of New York (USA)
Chem-Master International, Inc. (USA)
Inventeur(s)
Johnson, Francis
Golub, Lorne
Abrégé
This invention provides a compound having the structure
This invention provides a compound having the structure
This invention provides a compound having the structure
wherein α, β, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NFκ-B activation in a population of cells.
C07C 49/255 - Composés non saturés comportant des groupes cétone liés à des atomes de carbone acycliques contenant des groupes éther, des groupes , des groupes ou des groupes
C07C 225/22 - Composés contenant des groupes amino et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné, au moins un des atomes d'oxygène, liés par des liaisons doubles, ne faisant pas partie d'un groupe —CHO, p. ex. aminocétones ayant des groupes amino liés à des atomes de carbone de cycles aromatiques à six chaînons du squelette carboné
C07C 235/78 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné avec des atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques d'un squelette carboné non saturé le squelette carboné contenant des cycles
C07C 235/80 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons doubles, liés au même squelette carboné avec des atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques ayant des atomes de carbone de groupes carboxamide et des groupes céto liés au même atome de carbone, p. ex. acéto-acétamides
C07C 237/20 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des groupes amino ayant les atomes de carbone des groupes carboxamide liés à des atomes de carbone acycliques du squelette carboné le squelette carboné contenant des cycles aromatiques à six chaînons
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Balu-Iyer, Sathy
Jarvi, Nicole
Abrégé
Provided is a method for determining if a protein will produce an immunogenic response. The immunogenic response may be correlated by the migration of dendritic cells in the presence of the protein. The method may be used as a screening tool to assess immunogenicity risk for proteins that could be administered subcutaneously.
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
72.
SYSTEM AND METHOD FOR HYDROGEN STORAGE AND SEPARATION OF HYDROGEN FROM BLENDED METHANE-HYDROGEN MIXTURES
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Mahajan, Devinder
Abrégé
A method and system for separating hydrogen and methane from a mixture of same, e.g. natural gas, comprising an activated mixed metal hydride and conditions effective, including in one practice select temperatures, pressures, and flow rates whereby unexpected levels of hydrogen absorption occur allowing the methane to be separately recovered for use or storage; the absorbed hydrogen can be used or stored for long durations without degradation. The method can be repeatedly cycled using the same mixed metal hydride solid absorbent to create efficiency.
73.
AMBIENT TEMPERATURE SINTERABLE SILVER NANOALLOY INKS AND PASTES
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Zhong, Chuan-Jian
Robinson, Richard
Wang, Shan
Yan, Shan
Shang, Guojun
Abrégé
Nanoparticles with a bimetallic silver-copper (AgCu) alloy composition with ambient (room temperature) sintering properties. The bimetallic alloy is formulated with nanoparticles which are contained in a stable nanoink or nanopaste. The nanoink or nanopaste can be printed on paper and other substrates and be sintered under room temperatures. A method of creating the AgCu composition is also provided.
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p. ex. de solutions
B22F 1/0545 - Dispersions ou suspensions de particules de taille nanométrique
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
C09D 11/033 - Encres d’imprimerie caractérisées par des particularités autres que la nature chimique du liant caractérisées par le solvant
C09D 11/037 - Encres d’imprimerie caractérisées par des particularités autres que la nature chimique du liant caractérisées par le pigment
74.
ALGINATE HYDROGEL MICROSTRANDS FOR STROMAL CELL ENCAPSULATION, MAINTENANCE AND IMPLANTATION
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Xie, Yubing
Kollampally, Sujith
Jorgensen, Matthew
Abrégé
A device and process for fabricating alginate hydrogel microstrands, and product produced thereby, that are advantageously used for stromal cell encapsulation and maintenance. The device has first reservoir including a cell-alginate solution therein that selectively intakes and expels the cell-alginate solution therefrom, and a second reservoir in fluid connection with the first reservoir, the second reservoir containing a cross-linker solution and selectively intakes the cell-alginate solution from the first reservoir and expels the combined cell-alginate solution and cross-linker solution therefrom. The second reservoir selectively expels the combined cell-alginate solution and cross-linker solution as cell-laden hydrogel microstrands. The reservoirs of the device can be interconnected syringes.
The Research Foundation for The State University of new York (USA)
Inventeur(s)
Madden, Patrick
Abrégé
A system and method of laying out an integrated circuit, comprising defining a netlist of circuit elements comprising a plurality of macro blocks and standard cells of the integrated circuit, each macro block and standard cell having a respective area requirement; obtaining and storing a hierarchical abstract relative positioning (SHARP) of the circuit elements by at least one of repeatedly partitioning the netlist using bisection, and inducing cut lines into an abstract placement generated by an analytic placement tool; defining a plurality of arrangements of the macro blocks and standard cells within a respective region utilizing the SHARP; legalizing the plurality of arrangements to form legalized regions, each legalized region meeting the area requirements of the circuit elements within each respective region; and merging the legalized regions to generate a set of potential placements.
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERISTY OF NEW YORK (USA)
Inventeur(s)
Sanyal, Arindam
Seo, Jae-Sun
Damodaran, Vasundhara
Liu, Ziyu
Abrégé
System and method to improve the linearity of vector matrix multipliers (VMMs) by including (1) delta-sigma modulators that convert the input and output activations into binary pulse trains, (2) charge-domain computation in each SRAM cell that removes the nonlinear dependency on bitline voltage of the result of the multiplication and allows rail-to-rail output swing, and (3) a CMOS switch that transmits input activation to the capacitor in the SRAM cell, which improves linearity by suppressing the switch threshold voltage dependence on input activation voltage.
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Miller, Ronald
Abrégé
A diabetic foot examination device that monitors the progress of diabetic ulcers in a human foot based upon using, at least, visible light illumination. The device includes a body with a diagnostic pane located on an upper structure of the body and held at an angled relation to the base. The diagnostic pane is at least partially transparent to visible light and supports at least one foot placed thereupon. There is a camera affixed to the body that, at least, detects visible light and is positioned to view a foot placed against the diagnostic pane to generate diagnostic data from the detected illumination. An illumination source is affixed to the body to project light at the diagnostic pane. There is also a computer platform in communication with the camera and illumination source to control illumination, receive diagnostic data from the camera, and then create a diabetic ulcer diagnostic data.
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Seitllari, Aksel
Abrégé
A system and method for testing the durability of a cylindrical asphalt sample that is held within an apparatus and a load cell is moved by an actuator to apply a range of predetermined force against the cylindrical asphalt sample. The actuator is controlled by a computer device, further senses the resistance of the cylindrical asphalt sample to the predetermined force and communicates the sensed resistance data to the computer device. The computer device uses a Timoshenko Beam Theory (TBT) Model or a Viscoelastic Continuum Damage (VECD) Model to determine the deflection in the cylindrical asphalt sample to determine a durability measurement of the asphalt based upon the determined deflection.
G01N 3/20 - Recherche des propriétés mécaniques des matériaux solides par application d'une contrainte mécanique en appliquant des efforts permanents de flexion
G01N 3/06 - Adaptations particulières des moyens d'indication ou d'enregistrement
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Li, Huamin
Yao, Fei
Abrégé
Nanohybrid composites, methods of making nanohybrid composites, and uses of nanohybrid composites. A nanohybrid composite may be a binary nanohybrid composite comprising MXene and dual-phase MoS2. A nanohybrid composite may be a ternary nanohybrid composite comprising MXene, dual-phase MoS2, and a plurality of carbon nanotubes. A nanohybrid composite may be made by a method comprising contacting a liquid or liquid(s), a MXene or MXenes, a sulfur precursor or sulfur precursors, a molybdenum precursor or molybdenum precursors, optionally, an ammonium precursor or ammonium precursors, and, optionally, carbon nanotubes to form a reaction mixture; heating the reaction mixture, where the nanohybrid composite is formed. Anodes may comprise one or more nanohybrid composite(s). Devices, such as, for example, batteries or the like, may comprise one or more anode(s) comprising one or more nanohybrid composite(s) and/or one or more nanohybrid composite(s).
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
C25B 11/091 - Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé d’au moins un élément catalytique et d’au moins un composé catalytiqueÉlectrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique formé de plusieurs éléments catalytiques ou composés catalytiques
H01G 11/36 - Nanostructures, p. ex. nanofibres, nanotubes ou fullerènes
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 4/587 - Matériau carboné, p. ex. composés au graphite d'intercalation ou CFx pour insérer ou intercaler des métaux légers
H01M 4/86 - Électrodes inertes ayant une activité catalytique, p. ex. pour piles à combustible
H01M 4/90 - Emploi de matériau catalytique spécifié
80.
ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Ojima, Iwao
Haranahalli, Krupanandan
Del Poeta, Maurizio
Garg, Ashna
Abrégé
The present invention provides a compound having the structure:
The present invention provides a compound having the structure:
wherein
R3, R4, R5, R6, and R7 are each independently, H, halogen, CN, —CF3, —OCF3, —NO2, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, —OH, —OAc, —OR13, —COR13, —CH2OR13, —SH, —SR13, —SO2R13, —NH2, —NHR13, —NR14R15, —NHCOR12, or —CONR14R15;
R9, R10, R11, and R12 are each independently, H, CN, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —OAc, —COR13, —SH, —SR13, —SO2R13, —NH2, —NHR13, —NR14R15, —NHCOR12, or —CONR14R15;
wherein each occurrence of R13 is independently alkyl, alkenyl, alkynyl, aryl, or heteroaryl,
wherein each occurrence of R14 is independently —H, alkyl, alkenyl, alkynyl, aryl, or heteroaryl,
wherein each occurrence of R15 is independently —H, alkyl, alkenyl, alkynyl, aryl, or heteroaryl,
wherein when R14 is methyl, R15 is not methyl;
wherein at least one of R9, R10, R11, and R12 is not H;
wherein at least one of R3, R4, R5, R6, and R7 is not H.
C07C 251/86 - Hydrazones ayant des atomes de carbone, liés par des liaisons doubles, de groupes hydrazone liés à des atomes de carbone de cycles aromatiques à six chaînons
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/396 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à trois chaînons, p. ex. aziridine
C07D 229/02 - Composés hétérocycliques contenant des cycles de moins de cinq chaînons contenant deux atomes d'azote comme uniques hétéro-atomes du cycle contenant des cycles à trois chaînons
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Siu, Carrie
Whittingham, M. Stanley
Abrégé
The epsilon polymorph of vanadyl phosphate, ε-VOPO4, made from the solvothermally synthesized H2VOPO4, is a high-density cathode material for lithium-ion batteries optimized to reversibly intercalate two Li-ions to reach the full theoretical capacity at least 50 cycles with a coulombic efficiency of 98%. This material adopts a stable 3D tunnel structure and can extract two Li-ions per vanadium ion, giving a theoretical capacity of 305 mAh/g, with an upper charge/discharge plateau at around 4.0 V, and one lower at around 2.5 V.
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
H01M 4/136 - Électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
82.
SYSTEM AND METHOD FOR SOLAR VAPOR EVAPORATION AND CONDENSATION
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Gan, Qiaoqiang
Yu, Zongfu
Liu, Zhejun
Song, Haomin
Singer, Matthew
Li, Chenyu
Abrégé
A solar vapor generator system and method are provided. In some embodiments, the system has near perfect energy conversion efficiency in the process of solar vapor generation below room temperature. Remarkably, when the operation temperature of the system is below that of the surroundings, the total vapor generation will be higher than the upper limit that can be produced by the input solar energy.
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Sammakia, Bahgat G.
Hadad, Yaser
Farahikia, Mahdi
Chiarot, Paul
Abrégé
A liquid cooled cold plate for removing heat from an electronic apparatus. The liquid cooled cold plate includes a support base and one or more regions of high heat flux cooling structures in thermal contact with the support base. Liquid flow channels for directing a cooling liquid to flow through the cooling structures determine the flow rate and pressure of the cooling liquid. The cooling structures may include cooling posts, cooling rods, cooling cones, cooling fins and/or a complex arrangement of interconnected cooling structures such as interconnected cooling rods. These structures may be of uniform size or non-uniform size. One or more of the liquid flow channels may include a liquid throttling zone. This liquid throttling zone can be oriented horizontally or vertically relative to the support base of the liquid cooled cold plate. 3D printing as well as other manufacturing techniques may be used to produce the cold plate.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Levy, Sasha
Liu, Xianan
Matsui, Takeshi
Miller, Darach
Li, Weiyi
Abrégé
Provided herein, inter alia, are methods and compositions for assembling oligonucleotide fragments in vivo. The methods bypass inefficient cloning methods and the requirement for expensive enzymes. The methods may further be used to assemble long fragments of DNA. The methods may be used to generate variant libraries and combinatorial libraries and may be used to trace biological processes. Also provided herein, inter alia, are methods for in vivo DNA barcoding of oligonucleotide sequences. Methods provided herein are contemplated to produce unique barcode-oligonucleotide fusion sequences for identifying and isolating the oligonucleotide sequences, e.g., from a mixture. Accordingly, also provided are methods of identifying an oligonucleotide from a mixture of oligonucleotides.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
C40B 50/06 - Procédés biochimiques, p. ex. utilisant des enzymes ou des micro-organismes viables entiers
85.
BC200 RNA DECOY COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES, INCLUDING LUPUS
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Tiedge, Henri
Muslimov, Ilham
Ginzler, Ellen
Abrégé
BC RNA decoys and methods of use thereof are disclosed which inhibit anti-BC antibodies from causing intraneuronal mislocalization of BC RNAs, thereby treating lupus.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Assanis, Dimitris
Longtin, Jon
Loprete, Jason
Abrégé
A biomass heater system and method, in particular, an intelligent biomass heater utilizing a minimal set of measurement sensors and a control strategy to actively modulate incoming air, enhancing stove combustion performance, and thereby eliminating user-error as a factor for emissions production. The heater implements methods to estimate critical performance metrics such as the heat release rate, instantaneous stove efficiency, combustion stoichiometry and biomass fuel moisture content using combinations of sensor reading such as the heater temperature, weight and airflow rates. These parameters are used in a feedback control algorithm to optimize the variable application of combustion air and reduce the burden on the operator by providing recommendations for refueling and replacement of components through automated, intelligent decision-making. The applied approach uses a combination of deep learning Neural Networks, Classification Models, and Reinforcement Learning to allow for a continuous prediction of emissions and operation mode and provide appropriate actuator adjustment.
C10B 53/02 - Distillation destructive spécialement conçue pour des matières premières solides particulières ou sous forme spéciale de matières contenant de la cellulose
F24B 1/187 - Dispositifs de commande pour la régulation de la combustion sensibles à certaines conditions
87.
RADIOLABELED COMPOSITIONS AND METHODS OF USE THEREOF
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Turkman, Nashaat
Abrégé
The present invention provides a compound which is a class-lla histone deacetylases (HDAC) inhibitor, a process of making the compound, a composition containing the compound and radiolabeling the compound for use in positron emission tomography (PET) imaging, said compound having the structure:
The present invention provides a compound which is a class-lla histone deacetylases (HDAC) inhibitor, a process of making the compound, a composition containing the compound and radiolabeling the compound for use in positron emission tomography (PET) imaging, said compound having the structure:
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
88.
CONTROL SYSTEMS AND PREDICTION METHODS FOR IT COOLING PERFORMANCE IN CONTAINMENT
The Research Foundation for The State University of new York (USA)
Inventeur(s)
Alissa, Husam
Nemati, Kourosh
Sammakia, Baghat
Ghose, Kanad
Abrégé
A method of controlling a data center having a cold air cooling system, and at least one containment structure, comprising: determining a minimum performance constraint; determining optimum states of the cold air cooling system, a controlled leakage of air across the containment structure between a hot region and a cold air region, and information technology equipment for performing tasks to meet the minimum performance constraint, to minimize operating cost; and generating control signals to the cold air cooling system, a controlled leakage device, and the information technology equipment in accordance with the determined optimum states.
H05K 7/20 - Modifications en vue de faciliter la réfrigération, l'aération ou le chauffage
G05B 13/04 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Brouzes, Eric
Abrégé
The present disclosure is directed to a microwell array comprising a plurality of wells allowing for single cell genomics and methods for using such a microwell array in single cell genomics.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Eisaman, Matthew
Abrégé
The disclosure relates to enhancing alkalinity of brine, e.g. seawater, using bipolar membrane electrodialysis (BPMED) without removing divalent cations that otherwise cause scaling. In one embodiment, a BPMED is employed wherein the brine volumetric flow rate through a basification compartment is greater at a given current density than that through a brine compartment which increases the pH of the brine output while keeping it below the precipitation pH. In one embodiment, the spacer located in the basification compartment is thicker than spacers elsewhere in the BPMED so as resist membrane distortion due to the increased hydrostatic pressure in the basification compartment given the greater volumetric flow. The brine output having increased alkalinity can be returned to the ocean to mitigate acidification and enable capture of atmospheric carbon dioxide.
C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
C02F 1/461 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse
C02F 1/469 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par séparation électrochimique, p. ex. par électro-osmose, électrodialyse, électrophorèse
C02F 1/66 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par neutralisationAjustage du pH
C02F 103/06 - Eau souterraine contaminée ou eau de lessivage
C02F 103/10 - Nature de l'eau, des eaux résiduaires ou des eaux ou boues d'égout à traiter provenant de carrières ou d'activités minières
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Titus, Albert
Prathap, Vaishak
Villalta, Alexander
Abrégé
A pHI sensor system, Integrated Circuit (IC) chip, and a method are provided. Embodiments of the pH sensor may a first p-channel ion-sensitive transistor (IST)-operational-transconductance-amplifier (PIOTA) and a second PIOTA. Each PIOTA may further include a p-channel IST, an n-channel load transistor having a source and drain, wherein each PIOTA may have a drain-to-source resistance different from each other. Each PIOTA may further include an operational-transconductance-amplifier (OTA). A differential sensor may be connected to the outputs of both PIOTAs, and an output from the differential sensor may indicate a change in pH. Each PIOTA may further have an n-type substrate, a potential of which may be varied to control sensitivity of pH change detection. The NMOS load transistors of one or both of the PIOTAs may be selected from a plurality of NMOS load transistors to enhance sensitivity.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Ren, Shenqiang
Sheng, Aaron
Islam, Abdullah
Abrégé
Provided is a method for making a conductive ink. The conductive ink may be made by reacting copper sulfate with sodium carbonate to obtain copper carbonate; reacting the copper carbonate with formic acid to obtain copper formate particles; and forming an ink. Also provided are inks made by a method described herein.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Sung, Woongje
Isukapati, Sundar
Abrégé
Embodiments herein include a substrate; a semiconductor layer formed over the substrate; a source formed in the semiconductor layer; a drain formed in the semiconductor layer, whereon the drain is disposed laterally relative to the source; and a gate.
H01L 29/417 - Electrodes caractérisées par leur forme, leurs dimensions relatives ou leur disposition relative transportant le courant à redresser, à amplifier ou à commuter
H01L 27/092 - Transistors à effet de champ métal-isolant-semi-conducteur complémentaires
H01L 29/16 - Corps semi-conducteurs caractérisés par les matériaux dont ils sont constitués comprenant, mis à part les matériaux de dopage ou autres impuretés, seulement des éléments du groupe IV de la classification périodique, sous forme non combinée
94.
SYSTEM AND METHOD FOR MODELING NEURONAL SYNAPTIC FUNCTIONALITY ON A COMBINED SOFTWARE AND HARDWARE ARCHITECTURE
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Paluh, Janet L
Chatterjee, Rounak
Mondal, Soham
Chowdhury, Souradeep
Raha, Arnab
Mukherjee, Amitava
Abrégé
A system and method for modeling neuronal synaptic functionality at least partially instantiated on an optimized computation core of one or more high-speed processors. The synaptic model is preferably created as a neural net and includes, at least, a presynaptic component with a presynaptic target having, at least, a plasticity parameter and activity spike strength. The model also includes a retrograde signaling component with a retrograde messenger that selectively generates a molecular uptake signal, and a postsynaptic receptor component. The retrograde messenger acts on a presynaptic target to modulate the plasticity parameter and activity spike strength of the presynaptic component based upon a calculated molecular uptake at the postsynaptic receptor component to generate the molecular uptake signal which is then transmitted to the presynaptic component.
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G06N 3/049 - Réseaux neuronaux temporels, p. ex. éléments à retard, neurones oscillants ou entrées impulsionnelles
G06N 3/063 - Réalisation physique, c.-à-d. mise en œuvre matérielle de réseaux neuronaux, de neurones ou de parties de neurone utilisant des moyens électroniques
95.
INTEGRATED MATRIX TRANSFORMER FOR A POINT-OF-LOAD CONVERTER, AND APPLICATIONS THEREOF
The Research Foundation for The State University of new York (USA)
Inventeur(s)
Sasmal, Tuhin Subhra
Das, Pritam
Abrégé
An integrated matrix transformer for point-of-load converters is provided. The matrix transformer has a smaller surface area and a reduced core volume that lowers core losses. The matrix transformer's winding pattern produces a larger magnetizing inductance which aids in attaining better accuracy for gate pulse generation on the synchronous side of a point-of-load converter and mitigates power reversal issues present in traditional point-of-load converters using traditional matrix transformers. A reduction of circulating current in the primary side is also achieved. The matrix transformer comprises: a plurality of elemental transformers, each elemental transformer comprising a core, primary and secondary, linked through upper and lower members. The elemental transformers are magnetically coupled through the upper and lower members such that a flux induced by primary has a return path through one other core. The primaries are wired in series, and the secondaries in parallel.
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Bhattacharjee, Arindam
Abrégé
Disclosed are agents and methods of using the agents to treat or prevent pain and/or induce anesthesia. The agents may be peptides, siRNAs, and/or shRNAs that target adaptin protein 2-clathrin mediated endocytosis (AP2-CME). Peptides of the present disclosure may contain the following sequence X1X2X3X4LX5 (SEQ ID NO:7), where X1 is D, E, S, or T, where the D, E, S, and/or the T is optionally phosphorylated, X2, X3, and X3 are independently chosen from any amino acid.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
97.
CLINICAL PERSONAL PROTECTIVE EQUIPMENT WITH INTEGRATED DISPLAY AND MEDICAL DEVICE CONTROL SYSTEM
The Research Foundation for the State University of New York (USA)
Inventeur(s)
Masoud, Hesham
Decker, Andrew
Abrégé
A clinical personal protection equipment (PPE) system, worn by a healthcare provider, that can include a data display and selectively controls medical equipment. The system includes a computer platform that selectively communicates with a network, such as a Wifi network, and selectively communicates with and controls one or more electronic devices, such as an interactive rotating hemostatic valve and Tuohy-Borst adapter. The headset fits about the head of user and includes a face shield. A camera is located on the headset and is in communication with the computer platform, the camera creating visual data of a forward view from the headset and transmitting the visual data to the computer platform.
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
98.
SELECTIVE OPTICAL AQUEOUS AND NONAQUEOUS DETECTION OF FREE SULFITES
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Schmitt, Lynn
Lees, Alistair
Abrégé
4-pyrrolylpyridine, a novel anion sensor, displays a substantial color loss upon addition of sodium sulfite in aqueous solvents. A variety of anions were tested, including halides, phosphates, sulfates, and hydroxide, but all solutions remained unchanged aside from the sulfite, which displayed bleaching. Described here is a method for which the exact concentration of sulfites in a consumer product can be determined. The test is sensitive over a broad range of sulfites, from 0.84 ppm to over 10,000 ppm, and is accurate with a standard deviation of 0.01 ppm.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
The Research Foundation for The State University of New York (USA)
Inventeur(s)
Nouh, Mostafa
Attarzadeh, Mohammad Ali
Callanan, Jesse
Abrégé
Embodiments of the present disclosure include metabeams with nonreciprocal dispersion. A host beam has a length along along a longitudinal axis and is configured to vibrate (oscillate) over its length. The vibration may be in a first direction perpendicular to the length of the host beam. A plurality of first resonators may be arranged in an array along the length of the host beam and extending from the host beam in a second direction which forms an angle (>0°) with respect to the first direction and an angle (>0°) with respect to the longitudinal axis of the host beam. Each first resonator has an arm having a first end attached to the host beam and an arm axis. The arm has a stiffness in the first direction which is selectively variable. A mass may be attached to the arm at a location which is spaced from the first end by a first distance. The stiffness of each first resonator arm is configured to be varied to impart nonreciprocal dispersion in the host beam.
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Ionita, Ciprian
Williams, Kyle
Bhurwani, Mohammad Mahdi Shiraz
Abrégé
A computer-implemented methods and systems are provided for predicting flow characteristics in a vasculature. The method includes obtaining time-series angiography data of a vasculature; determining vessel wall geometry within the vasculature; generating, using one or more processors, a set of collocation points within the time-series angiography data co-registered with the vessel wall geometry; and determining, using the one or more processors, a flow velocity and pressure at each collocation point using a physics-informed neural network (PINN) having an objective function based on the Navier-Stokes equation, the convection equation, and boundary conditions including the vessel wall geometry and the angiography data. In some embodiments, determining the flow velocity and pressure at each collocation point comprises minimizing a difference between a contrast intensity measured at each collocation point of the angiography data and an imputed contrast intensity calculated from the PINN-determined flow velocity and pressure at each collocation point.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux